Healthcare · Profile from Healthcare Research Companion
Purdue Pharma L.P.
The privately held, Sackler-family-owned drug company whose 1996 launch and aggressive marketing of OxyContin, an extended-release oxycodone pill, made it the emblem of the US prescription opioid epidemic. Purdue earned an estimated ~$35bn from OxyContin (reported), pleaded guilty to federal crimes twice (2007 and 2020), filed for bankruptcy in 2019, and lost a landmark Supreme Court case over the Sackler family's releases in 2024 before a revised ~$7.4bn settlement was confirmed in November 2025. The plan took effect on 1 May 2026, when Purdue's operating assets passed to a new company, Knoa Pharma, owned by the Knoa Foundation. It is the defining case in this knowledge base of how marketing claims about safety, owner cash extraction and weak oversight can destroy a company and harm a country.
At a glance
- Founded
- 1892, New York City, as Purdue Frederick Company; bought by the Sackler brothers in 1952
- Founders
- John Purdue Gray and George Frederick Bingham (1892); modern owners Arthur, Mortimer and Raymond Sackler (1952), all physicians
- Headquarters
- Stamford, Connecticut (from the 1970s; earlier New York and Norwalk, Connecticut)
- Ownership / structure
- Private limited partnership owned through trusts by the families of Mortimer and Raymond Sackler (the "A side" and "B side"); international sister companies under the Mundipharma and Napp names were also family-owned and are outside the US bankruptcy
- Leadership (2026)
- Run under Chapter 11 by CEO Craig Landau (from 2017) and a board without Sackler members (Sacklers left the board in 2018–19). Since 1 May 2026 the business is Knoa Pharma LLC, wholly owned by the Knoa Foundation (an independent 501(c)(4)), under an operating injunction and an independent monitor; Knoa's management team is not confirmed here
- Segment and buyer
- Branded and generic pain medicines (OxyContin, MS Contin, Butrans, Hysingla), laxatives (Senokot) and, later, overdose-reversal products; buyers are pharmacies and distributors; payers include Medicaid, Medicare Part D, commercial plans and patients
- Scale
- OxyContin US sales rose from ~$48m (1996) to ~$1bn+ (2000) and peaked at roughly ~$3bn a year around 2010–12 (reported, verify); Purdue revenue had fallen to ~$1bn or less by 2020 (verify)
- Capital / value
- Family-owned; Purdue made ~$10.7bn of payments for the Sackler families' benefit between 2008 and 2017, including taxes, of which ~$4.1bn was cash to family members (AlixPartners audit filed in the bankruptcy, December 2019); the family says more than half went on taxes or was reinvested abroad
- Signature moves (incl. failures)
- Sackler purchase (1952); MS Contin and Contin technology (1984); OxyContin launch (1996); 2007 federal guilty plea (~$600m+); abuse-deterrent reformulation (2010); McKinsey-designed sales push ("Evolve to Excellence"/"Turbocharge", 2013–17); Chapter 11 (2019); second federal guilty plea (2020, ~$8.3bn); Harrington v. Purdue Pharma (2024); ~$7.4bn plan confirmed (2025)
8 strategic moves analysed
Each one gets a full strategy file in the companion: context, the decision, the financing, what happened, and the lesson.
1952
Sackler Purchase of Purdue Frederick
Acquisition (founding of the modern company)
1996
OxyContin Launch
Launch
2007
Federal Guilty Plea Misbranding
Regulatory settlement / criminal plea
2010
Abuse Deterrent Reformulation
Product change / lifecycle management
2013
McKinsey Sales Turbocharge
Go-to-market strategy (consultant-designed sales programme)
2019
Chapter 11 Bankruptcy
Bankruptcy
2020
Second Federal Guilty Plea
Regulatory settlement / criminal plea
2024
Harrington Ruling and Final Settlement
Litigation / bankruptcy plan